The longitudinal evaluation performed in 70 COVID-19 patients showed a significant decrease in sCD163 plasmatic levels at T7 compared to T0 (1060 [766-1350] and 1209 [823-1563], respectively; p=0.0211). This evidence concerns the gene CD163 and COVID-19.